NEW YORK, July 28 (GenomeWeb News) - As part of a collaborative research project led by ImperialCollege, London, Prolexys Pharmaceuticals will create a comprehensive protein-protein interaction map of Mycobacterium tuberculosis, the bacterium that causes tuberculosis, using its HyNet and HySpec platforms, the company said today in a statement.
Prolexys did not disclose detailed financial terms of the deal.
"The detailed protein interaction map will shed a light on potential mechanisms of TB latency and therefore facilitate the discovery of drugs that eliminate the latent infection," Gary Schoolnik, a consortium member and a professor of medicine at StanfordUniversity, said in the statement.
About 2 billion people worldwide carry latent TB, according to the statement.
The consortium is supported by a $20 million grant toImperialCollegefrom the Grand Challenges in Global Health initiative, which is itself supported by the Bill & Melinda Gates Foundation, the Wellcome Trust, and the Canadian Institutes of Health Research, Prolexys said.